

## MODERN DIAGNOSTIC &amp; RESEARCH CENTRE LTD.

## IPO NOTE

IPO Price Band: INR 85 to 90 per share

M.Cap: ~INR 135.89 Cr.

Recommendation: May Subscribe

**ABOUT:** Incorporated in 2012, Company is a healthcare service provider offering a "one-stop solution" for diagnostic testing, integrating both Pathology (lab testing) and Radiology (imaging) services under one roof. The business began in 1985 as a proprietary firm named 'Modern X-Ray and Clinical Lab'. The company operates on a Hub and Spoke model, where specimens collected from various points are transported to centralized laboratories for testing. As of September 30, 2025, the network consists of 21 centers across 8 states, comprising 18 laboratories and 3 diagnostic centers.

**INVESTMENT RATIONALE:****Geographic Expansion:**

- The company plans to utilize INR 20.68 Crore of its Net Issue Proceeds to purchase medical equipment for setting up a new comprehensive diagnostic centre in Lucknow and six new labs across Delhi, Meerut, Kanpur, Aligarh and Chandigarh.
- While the company currently derives 65-68% of its revenue from Haryana, it is actively expanding its footprint in Uttar Pradesh, Rajasthan, and Punjab to reduce geographic concentration.

**B2B Segment Scaling**

- Revenue contribution from B2B clients (hospitals, nursing homes, and clinics) has consistently risen from 46.58% in FY23 to 59.57% in the period ended June 30, 2025.

**Better Operating Metrics**

- Tests conducted jumped from 187.9 lakhs in FY23 to 324.3 lakhs in FY25 which is an absolute increase of 72% over 2 years.
- Revenue per patient increased from INR 488.5 in FY23 to INR 590.5 in Jun'25 which is approx. 21% increase.

**BRIEF FINANCIALS:**

Particulars (INR Cr.)	FY23	FY24	FY25	Q1FY26
Revenue (excl. other inc.)	56.3	67.1	77.9	22.5
Growth Rate Y-o-Y %	-	19.3%	16.1%	
EBITDA (excl. other inc.)	(1)	11.1	18.0	5.9
PAT	(5.7)	5.8	9.0	3.0
Gross Margin %	68.9%	73.7%	75.9%	74.8%
EBITDA % (excl. other inc.)	(1.8%)	16.5%	23.0%	26.1%
PAT %	(10.1%)	8.4%	11.4%	13.2%
Debt (Short+Long)	15.3	20.5	22.1	30.4
Equity	6.0	11.8	20.7	23.7
Debt/Equity	2.6x	1.7x	1.1x	1.3x
NWC	2	5	9	11
NWC (days)	12	26	44	43
NWC includes Inventory, Receivables & Payables; & NWC days is computed as % of rev.				
ROE %	(64.92)%	65.4%	55.21%	13.49%*
ROCE %	(17.18)%	25.57%	36.18%	9.54%*
CFO / EBITDA %		71.7%	76.4%	(107.4%)

\*Not Annualized

**IPO VALUATION & VIEW:**

Issue is valued at P/E ratio of 15.2x based on FY25 PAT. Strengths of experienced promoter, strong financial turnaround with margin expansion, upcoming new centers, favorable tailwinds for healthcare industry are offset by small scale, competitive intensity & ramp up of operations from IPO led capex, we assign a MAY SUBSCRIBE to this issue.

**ISSUE SUMMARY**

Particulars	Details
Price Band (INR)	85 to 90
Face Value (INR)	10
Implied M.Cap (INR Cr.)	135.89
Exchange	BSE SME
Min. Lot Size (Retail   HNI)	3,200   4,800
Issue Opens on	31-Dec'25
Issue Closes on	02-Jan'26
Listing Date	07-Jan'26
No. of shares pre-issue (#)	1,10,00,000
Fresh Issue of Shares (#)	40,99,200
Offer for Sale (#)	-
No. of shares post-issue (#)	1,50,99,200
Funds Mobilized (INR Cr.)	
(a) Fresh Issue of Shares	36.89
(b) Offer for Sale	0.0
IPO Reservation	
(a) QIB shares offered	<=50%
(b) Retail shares offered	>=35%
(c) NII (HNI) shares offered	>=15%
Registrar	MUFG Intime India
Book Running Lead Managers	Beeline Capital
Objects of Issue (INR Cr.)	
(a) Funding capex for purchase of Medical Equipment	20.69
(b) Funding working capital	8.00
(c) Repayment of borrowings	1.00
(d) General Corporate Purposes	[●]

**SHAREHOLDING**

Particulars	Pre-Issue	Post-Issue
Promoter & Promoter Group	99.99%	72.85%
Public	0.01%	27.15%
<b>Total</b>	<b>100.00%</b>	<b>100.00%</b>

**KEY RISKS / MONITORABLES**

- Geographical Concentration: 65.8% of revenue (30 Jun'25) comes from single state – Haryana.
- Company has a high debt to equity ratio. However, with IPO proceeds for funding working capital, debt to equity ratio is expected to come down going forward.
- Regulatory Intervention Risk: Government may cap diagnostic test prices.
- Diagnostics industry is highly competitive with presence of national chains, regional labs and price-aggressive standalone centers.
- Related Party Transactions such as rent to the Promoter (INR 82.09 Lakhs in FY25) remains a key monitorable.

## MODERN DIAGNOSTIC &amp; RESEARCH CENTRE LTD.

## IPO NOTE

IPO Price Band: INR 85 to 90 per share

M.Cap: ~INR 135.89 Cr.

Recommendation: May Subscribe

 Revenue Breakup :

Particulars	FY23	FY24	FY25	June 30, 2025
Pathology	72.97%	74.66%	75.23%	80.70%
Radiology	27.03%	25.34%	24.77%	19.30%
B2B	46.58%	49.07%	51.34%	59.57%
B2C	53.42%	50.93%	48.66%	40.43%

**B2B (Business-to-Business):** Includes revenue from hospitals, nursing homes, clinics, and other healthcare establishments. B2B revenue increasing (46.58% in FY23 → 51.34% in FY25)

**B2C (Business-to-Consumer):** Includes revenue from direct customers, walk-ins, home appointments, and referrals.

 Operational Metrics and Unit Economics:

Particulars	FY23	FY24	FY25	June 30, 2025
Number of Tests Conducted (In Lakhs)	187.95	191.91	324.37	90.16
Number of Patients Served (In Lakhs)	11.52	12.41	13.68	3.81
Average Revenue Per Patient (₹)	488.56	540.94	569.78	590.58

**Geographic Concentration:** For the period ended June 30, 2025, 65.80% of total domestic revenue came from Haryana. This is a decrease from 68.24% in FY25 and 72.20% in FY24, indicating a gradual diversification though dependence remains high.

The company has 2 NABH accreditations for its imaging services, both located in Gurugram and 5 NABL-accredited labs in Gurugram, Srinagar, Amritsar, Yamuna Nagar, Bareilly and Guwahati.

Revenue % from State	June 30, 2025
Haryana	65.80%
Jammu & Kashmir	8.51%
Uttar Pradesh	7.95%
Rajasthan	6.16%
West Bengal	4.15%

 Promoters:

- **Dr. Devendra Singh Yadav** (age 72 years) is Promoter, Chairman and Managing Director of the Company having 40 years of experience in the medical diagnostic and research field. He holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Medical College Rohtak and a Diploma in Medical Radio-diagnosis (DMRD) from the University of Delhi.
- **Dr. Deepali Yadav** (age 42 years) is the Promoter and Whole Time Director of the Company. She holds a Doctor of Medicine (MD) degree in Radio-diagnosis from HIHT University, Dehradun. She specializes in CT Coronary Angiography, CT/MRI case reporting, and ultrasound-guided FNAC.

 Peer Comparison: As per RHP, peers mentioned are Vijaya Diagnostics Ltd.

Particulars (INR Cr.)	FY23	FY24	FY25	FY23	FY24	FY25
	Modern Diagnostics			Vijaya Diagnostic		
Operating Revenues	56.3	67.1	77.9	459	548	681
Rev. growth rate % (Y-o-Y)	-	19.3%	16.1%	(1%)	19%	24%
Gross Margins %	68.9%	73.7%	75.9%	87.1%	88%	87.5%
EBITDA Margins %	(1.8%)	16.5%	23.0%	39.6%	40.3%	40.1%
PAT Margins %	(10.1%)	8.4%	11.4%	17.9%	21%	20.5%
Debt	15.3	20.5	22.1	248	259	320
Equity	6	11.8	20.7	545	657	796
D/E	2.6x	1.7x	1.1x	0.45x	0.39x	0.4x
CFO / EBITDA %	(12%)	71.7%	76.4%	90%	83%	82%
NWC Days	12	26	44	9	14	11
Market Cap (INR Cr.)	135.89			10,632		
PE Ratio (FY25)	15.2x			74x		

## **STANDARD DISCLOSURES:**

- Research Analyst has served as an officer, director or employee of subject company(ies): **No**
- We or our associates have received compensation from the subject company(ies) in the past 12 months: **No**
- We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: **No**
- We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months -**No**
- We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report -**No**
- We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- **No**
- Nature of financial interest in subject company, if any -**Nil**
- We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report - **No**
- Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-**No**.
- We or our Associates or Research Analyst are engaged in market making of subject company - **No**
- By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
- There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.

## **REGULATORY DISCLOSURES:**

Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).

Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.

The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.

For any queries or grievances: Mr. Nishant Gupta | Email: [nishant.gupta@mcapital.in](mailto:nishant.gupta@mcapital.in) or [guptanishant.iimi@gmail.com](mailto:guptanishant.iimi@gmail.com) | Contact Number: 8171433387 | Website: [www.mcapital.in](http://www.mcapital.in) | Twitter: [@Mcapital\\_In](https://twitter.com/Mcapital_In)

- Equity Research Analyst for this report: Mr. Shubham Upadhyay (shubham.upadhyay@mcapital.in)

## **RATING RATIONALE:**

Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst's valuation for a stock.

- Buy:> 15%
- Hold: -5% to 15%
- Reduce: -15% to -5%
- Sell: <-15%